2 results about "Imidaclothiz" patented technology

The present invention relates to combinations of a compound of formula (A-1) with a compound selected from the group consisting of dimpropyridaz, emamectin and isocycloseram, bentioflumin, pioxaniliprole, isoflualanam, cybenzoxasulfyl, vinylfluthrin, cyclobunofen, flupymezotiaz, fentiazoluron, 1-(1,2-dimethylpropyl)-5-methyl-N-prop-2-ynyl-N-(3-pyridyl)pyrazole-4-carboxamide, 1 -[4- [5-ethylsulfonyl-1-methyl-4-[3-methyl-6-(trifluoromethyl)imidazo[4,5-b]pyridin-2-yl]imidazol-2- yl]phenyl]cyclopropanecarbonitrile, [(Z)-[[3-ethylsulfonyl-5-[4-(trifluoromethoxy)phenyl]-2-pyridyl]-[[5- (trifluoromethyl)-2-pyridyl]amino]methylene]amino] acetate, 3-[3-ethylsulfonyl-5-[4- (trifluoromethoxy)phenyl]-2-pyridyl]-4-[5-(trifluoromethyl)-2-pyridyl]-1,2,4-oxadiazol-5-one, 1-(4- chlorophenyl)-2-fluoro-4-methyl-5-(2,2,2-trifluoroethylsulfanyl)benzene, and emamectin benzoate; and to methods of controlling or preventing damage to plants using such combinations; and to formulations, concentrates and seed treatments comprising such combinations.

The invention discloses a hederagenin C-23 heterocyclic ester derivative as well as a preparation method and application thereof, and belongs to the technical field of organic chemistry. The structure of the derivative is shown in the specification, wherein R represents pyrazole, thiazole, oxazole, furan, pyrimidine, pyrazine or indole. Pharmacological tests show that part of hederagenin C-23 heterocyclic ester derivatives (T-BZ, T-SZ, T-EZ, T-MD and TBQ) prepared by the invention have better MDR reversal activity than verapamil, can significantly increase the sensitivity (p < 0.0001) of drug-resistant KBV cells to paclitaxel, are P-gp inhibitors with more excellent MDR reversal activity, can be used in combination with common antitumor drugs, and can be used for preparing drugs for treating tumors. The good anti-tumor activity is realized.